Protein Summary
Protease involved in KMT2A/MLL1 processing and, consequently, in the correct expression of the early HOXA gene cluster. This gene encodes an endopeptidase that cleaves specific substrates following aspartate residues. The encoded protein undergoes posttranslational autoproteolytic processing to generate alpha and beta subunits, which reassemble into the active alpha2-beta2 heterotetramer. It is required to cleave MLL, a protein required for the maintenance of HOX gene expression, and TFIIA, a basal transcription factor. Alternatively spliced transcript variants have been described, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]
- ENST00000337743
- ENSP00000338624
- ENSG00000089123
- C20orf13
- C20orf13
- dJ585I14.2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
histone modification site profile | 0.91 | ||
kinase perturbation | 0.76 | ||
transcription factor perturbation | 0.74 | ||
transcription factor binding site profile | 0.68 | ||
tissue sample | 0.64 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 45.56 (req: < 5)
Gene RIFs: 18 (req: <= 3)
Antibodies: 179 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 45.56 (req: >= 5)
Gene RIFs: 18 (req: > 3)
Antibodies: 179 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 6
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 1
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0